Atorvastatin Side Effects and Monitoring

Patient Risk Factors

The American College of Cardiology notes that advanced age (especially >80 years), with women at higher risk than men, is a risk factor for muscle problems in patients taking atorvastatin 1, 2
Small body frame and frailty are also risk factors for muscle problems in patients taking atorvastatin, as reported by the American College of Cardiology 1, 2
Multisystem disease (e.g., chronic renal insufficiency, especially due to diabetes) increases the risk of muscle problems in patients taking atorvastatin, according to the American College of Cardiology 1, 2
The American College of Cardiology recommends that patients with multiple medications, perioperative periods, and higher doses of atorvastatin should be monitored closely for muscle problems 1, 2
Concomitant medications that interact with atorvastatin, such as fibrates, cyclosporine, macrolide antibiotics, azole antifungals, niacin, and protease inhibitors, increase the risk of adverse effects, as noted by the American College of Cardiology 1

High-dose atorvastatin (80 mg) has been associated with a six-fold increase in enzymatic signs of liver damage compared to lower doses (from 0.2% to 1.2%), as reported in the European Heart Journal 3

The American College of Cardiology recommends baseline liver function tests (ALT, AST) before starting atorvastatin therapy, and follow-up liver function tests approximately 12 weeks after starting therapy, then annually or more frequently if indicated 1, 2
Baseline CK (creatine kinase) levels should be measured before starting atorvastatin therapy, and patients should be monitored for muscle symptoms at 6-12 weeks after starting therapy and at each follow-up visit, as recommended by the American College of Cardiology 1, 2
The American College of Cardiology suggests that CK measurements should be obtained when patients report muscle soreness, tenderness, or pain 1, 2
Elderly patients, particularly thin or frail older women, should use atorvastatin more cautiously, as advised by the American College of Cardiology 1, 2
The American College of Cardiology recommends considering withholding atorvastatin during hospitalization for major surgery 1, 2

Hypersensitivity reactions can occur in patients taking atorvastatin, as noted in the Journal of the American College of Cardiology 4

The American Heart Association recommends monitoring for muscle symptoms at 6-12 weeks after starting atorvastatin, then at each follow-up visit, as muscle-related symptoms are the most common side effect, occurring in 5-20% of real-world patients 5
Nasal congestion, sore throat, runny nose, diarrhea, gastrointestinal upset, urinary tract infection, and trouble sleeping are common side effects of atorvastatin, according to the American College of Cardiology 5

The American College of Cardiology warns that patients taking immunosuppressants, such as cyclosporine, tacrolimus, everolimus, or sirolimus, require close monitoring of creatinine kinase and muscle symptoms when taking atorvastatin doses >10 mg daily 5
The Centers for Disease Control and Prevention recommend that patients on HIV therapy, including protease inhibitors, use atorvastatin with caution and consider reduced doses due to CYP450 interactions 6

The American Heart Association advises against combining atorvastatin with gemfibrozil due to significantly increased rhabdomyolysis risk, and recommends using fenofibrate instead if fibrate therapy is needed 7
The American College of Cardiology recommends avoiding the combination of atorvastatin and colchicine, as it produces synergistic muscle-related toxicity through both pharmacokinetic and pharmacodynamic mechanisms 8

The American Diabetes Association recommends continuing atorvastatin and emphasizing lifestyle modifications, such as regular moderate-intensity physical activity, healthy dietary pattern, and modest weight loss, if diabetes develops during atorvastatin therapy 6
The American College of Cardiology suggests temporarily discontinuing atorvastatin until symptoms resolve, evaluating other causes, and rechallenging with a lower dose or alternative statin for mild-moderate muscle symptoms with normal or mildly elevated CK 8

High-dose atorvastatin (80 mg) carries a significantly higher risk of myopathy and rhabdomyolysis, with the SEARCH trial documenting 8 cases of myopathy and 7 cases of rhabdomyolysis in patients on simvastatin 80 mg with amiodarone versus zero cases at 20 mg 9
Amiodarone significantly increases atorvastatin levels by ~75%, with the SEARCH trial showing 8.8-fold increased myopathy risk when combined with high-dose statins 9